Chromatin states define tumour-specific T cell dysfunction and reprogramming

被引:641
|
作者
Philip, Mary [1 ,3 ]
Fairchild, Lauren [2 ]
Sun, Liping [4 ]
Horste, Ellen L. [1 ]
Amara, Steven C. [1 ]
Shakiba, Mojdeh [1 ,5 ]
Scott, Andrew C. . [1 ,5 ]
Viale, Agnes [4 ]
Lauer, Peter [6 ]
Erghoub, Taha M. [5 ,7 ]
Hellmann, Matthew D. [5 ,8 ]
Wolchok, Jedd D. [5 ,7 ,9 ]
Leslie, Christina S. [2 ]
Schietinger, Andrea [1 ,5 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA
[3] Weill Cornell Med Coll, Triinst Training Program Computat Biol & Med, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, Integrated Genom Operat, New York, NY 10065 USA
[5] Cornell Univ, Weill Cornell Med Coll, New York, NY 10065 USA
[6] Aduro Biotech Inc, Berkeley, CA 94720 USA
[7] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, New York, NY 10065 USA
[8] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY 10065 USA
[9] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA
关键词
DIFFERENTIAL EXPRESSION; TRANSCRIPTIONAL CONTROL; CANCER; EFFECTOR; LANDSCAPE; PROTEINS; BLOCKADE; ANTIGEN; BIAS;
D O I
10.1038/nature22367
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumour-specific CD8 T cells in solid tumours are dysfunctional, allowing tumours to progress. The epigenetic regulation of T cell dysfunction and therapeutic reprogrammability (for example, to immune checkpoint blockade) is not well understood. Here we show that T cells in mouse tumours differentiate through two discrete chromatin states: a plastic dysfunctional state from which T cells can be rescued, and a fixed dysfunctional state in which the cells are resistant to reprogramming. We identified surface markers associated with each chromatin state that distinguished reprogrammable from non-reprogrammable PD1(hi) dysfunctional T cells within heterogeneous T cell populations from tumours in mice; these surface markers were also expressed on human PD1(hi) tumour-infiltrating CD8 T cells. Our study has important implications for cancer immunotherapy as we define key transcription factors and epigenetic programs underlying T cell dysfunction and surface markers that predict therapeutic reprogrammability.
引用
收藏
页码:452 / +
页数:21
相关论文
共 50 条
  • [41] Identifying the epigenetic code of tumor-specific CD8 T cell dysfunction and therapeutic reprogramming
    Philip, Mary
    Fairchild, Lauren
    Sun, Liping
    Viale, Agnes
    Camara, Steven
    Horste, Ellen
    Merghoub, Taha
    Wolchok, Jedd D.
    Leslie, Christina S.
    Schietinger, Andrea
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [42] Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer
    Betts, Gareth
    Jones, Emma
    Junaid, Syed
    El-Shanawany, Tariq
    Scurr, Martin
    Mizen, Paul
    Kumar, Mayur
    Jones, Sion
    Rees, Brian
    Williams, Geraint
    Gallimore, Awen
    Godkin, Andrew
    GUT, 2012, 61 (08) : 1163 - 1171
  • [43] Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses
    Cheng, Liang
    Du, Xuexiang
    Wang, Zheng
    Ju, Jianqi
    Jia, Mingming
    Huang, Qibin
    Xing, Qiao
    Xu, Meng
    Tan, Yi
    Liu, Mingyue
    Du, Peishuang
    Su, Lishan
    Wang, Shengdian
    JOURNAL OF HEPATOLOGY, 2014, 61 (06) : 1297 - 1303
  • [44] Dual oncolytic viral immunotherapy generates large polyfunctional tumour-specific CD8+T cell responses that infiltrate immunosuppressive tumors
    Stojdl, David
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Immunological recovery and tumour-specific immunotherapeutic approaches to post-autologous haematopoietic stem cell transplantation
    Guillaume, T
    Rubinstein, DB
    Symann, M
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 1999, 12 (1-2) : 293 - 306
  • [46] Naive Tumour-Specific CD4+ T Cells were Efficiently Primed in Acute Lymphoblastic Leukaemia
    Noyan, F.
    Lieke, T.
    Taubert, R.
    Sievers, M.
    Dywicki, J.
    Hapke, M.
    Falk, C. S.
    Manns, M. P.
    Jaeckel, E.
    Hardtke-Wolenski, M.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2014, 80 (03) : 161 - 168
  • [47] In vivo enhancement of tumour-specific T cells via peptide-MHC-pseudotyped retroviral gene delivery
    Kwong, Hugo
    Borrow, Persephone
    NATURE REVIEWS IMMUNOLOGY, 2025, 25 (02) : 76 - 76
  • [48] Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous uterine serous papillary cancer
    Santin, AD
    Bellone, S
    Ravaggi, A
    Roman, JJ
    Pecorelli, S
    Parham, GP
    Cannon, MJ
    BRITISH JOURNAL OF CANCER, 2002, 86 (01) : 151 - 157
  • [49] Despite generating a weak tumour-specific CTL response during tumour progression chemotherapy is only effective in elderly mice if T cells are present
    Nelson, D.
    Spowart, J.
    Crabb, H.
    Dye, D.
    Fox, S.
    Metharom, P.
    Proksch, S.
    Jackaman, C.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 873 - 873
  • [50] SIN3-HDAC complex-associated factor, a chromatin remodelling gene located in the 12p amplicon, is a potential germ cell tumour-specific oncogene
    Jhuang, Yu-Ling
    Yang, Chun-Wei
    Tseng, Yu-Fen
    Hsu, Chia-Lang
    Li, Huei-Ying
    Yuan, Ray-Hwang
    Jeng, Yung-Ming
    JOURNAL OF PATHOLOGY, 2022, 258 (04): : 353 - 365